Blocking CCR10 Expression Activates m6A Methylation and Alleviates Vascular Endothelial Cell Injury

Abstract

Background: Cardiovascular disease, one of the most common types of disease in clinical practice today, carries a very high risk of disability and death. This research aims to examine genome-wide changes in injured human dermal microvascular endothelial cells (HDMECs) using the Ribonucleic Acid sequencing (RNA-Seq) technique, and to search for key genes influencing N6-methyladenosine (m6A) methylation, thus gaining new insights into future clinical diagnosis and treatment of cardiovascular diseases (CVDs) and laying a foundation for follow-up research. Methods: Impaired HDMECs (injury group), established by endotoxin intervention, were analyzed by RNA-Seq for differentially expressed genes (DEGs) relative to normal HDMECs (control group). Then, DEGs that might be associated with m6A methylation were selected for expression blocking to observe m6A methylation alterations. The migration, angiogenesis, and inflammatory response of damaged HDMECs were detected by cell scratch assay, western blotting, and Enzyme-linked Immunosorbent Assay (ELISA) experiments, respectively. Results: In this study, 20 DEGs were screened out from the two groups by RNA-Seq, of which 17 were up-regulated and 3 were down-regulated. The C-C motif chemokine receptor 10 (CCR10) was selected for subsequent analysis. Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) identified elevated CCR10 expression and reduced m6A methylation levels in the injury group (p < 0.05). After blocking CCR10 expression in damaged HDMECs by BI6901 (a CCR10 specific blocker) m6A methylation, cell activity, vascular endothelial growth factor A (VEGFA) and CD31 protein expression, as well as relative length and branches of tube formation were found to be increased compared with the injury group, while the levels of inflammatory factors interleukin-1 (IL-1), interleukin-1 (IL-6) and tumor necrosis factor-α (TNF-α) were decreased (p < 0.05). Conclusions: Blocking CCR10 expression can activate m6A methylation, promote cell activity, inhibit inflammatory reactions and alleviate HDMEC injury, which may become a breakthrough in future diagnosis and treatment of cardiovascular diseases.

The therapeutic effect of phellopterin on colitis-associated cancer and its effects on TLR4/NF-κB pathway and macrophage M2 polarization

“…At present, it is generally believed that the pathogenesis of inflammation-related CC follows the "inflammation-dysplasia-canceration" pathway, in which inflammatory factors, immune microenvironment, and TLR4/NF-ĸB related pathway play an important role in the pathogenesis of inflammation-related CC (22). IL-6 is a kind of pro-inflammatory factor, which is involved in mediating cellular immune response and is closely related to tumor size and metastasis (23). TNF-α, mainly produced in the initiation of inflammation, is a pro-inflammatory factor (24).…”

Vaginal microecological imbalance and expression of serum inflammatory factors in pregnant women with group B streptococcus infection and pregnancy outcome

“…the inflammatory state of the body, which can cause inflammatory responses, including IL-6, TNF-α, IL-1β, etc. (12). During pregnancy, the level of inflammatory factors may increase, which may have an impact on the outcome of pregnancy (13).…”

N6-methyladenosine modification of KLF2 may contribute to endothelial-to-mesenchymal transition in pulmonary hypertension

“…Moreover, RNA modifications are also essential in regulating endothelial dysfunction. Elevation of C-C motif chemokine receptor 10 (CCR10) decreases m 6 A methylation, promoting endothelial injury [ 25 ]. Similarly, human cytomegalovirus accelerates endothelial apoptosis through METTL3 and YTHDF3-mediated m 6 A modification [ 26 ].…”